Moderna, Inc.

NasdaqGS:MRNA

Sector

🏥 Health Care

Industries

🧬 Biotechnology

🔬 Clinical Trials

💉 Vaccines

Location

United States

Market Cap

USD 10.36 B

Share Price

USD 26.80

Avg Daily Volume

10,937,573

Change (1 day)

4.40%

Change (1 year)

-80.44%

Change (YTD)

-35.55%

Moderna, Inc. Common Stock Issued for the Trailing 12 Months (TTM) ending March 31, 2025: USD 54.00 M

Moderna, Inc. Common Stock Issued is USD 54.00 M for the Trailing 12 Months (TTM) ending March 31, 2025, a 3.85% change year over year. Common stock issued is cash received from issuing new shares of the company’s common stock.

Moderna, Inc. Common Stock Issued for the Trailing 12 Months (TTM) ending March 31, 2024 was USD 52.00 M, a 15.56% change year over year.
Moderna, Inc. Common Stock Issued for the Trailing 12 Months (TTM) ending March 31, 2023 was USD 45.00 M, a -58.33% change year over year.
Moderna, Inc. Common Stock Issued for the Trailing 12 Months (TTM) ending March 31, 2022 was USD 108.00 M, a -91.03% change year over year.
Moderna, Inc. Common Stock Issued for the Trailing 12 Months (TTM) ending March 31, 2021 was USD 1.20 B, a 125.86% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Common Stock Issued	Common Stock Repurchased	Free Cash Flow	Operating Cash Flow

NasdaqGS: MRNA

Moderna, Inc.

CEO	Mr. Stephane Bancel
IPO Date	Dec. 7, 2018
Location	United States
Headquarters	200 Technology Square
Employees	5,800
Sector	🏥 Health Care
Industries Biotechnology 🔬 Clinical Trials 💉 Vaccines

Description

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.